The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilization in our institution. Such patients were distributed into three groups: those who proceeded to steady-state bone marrow (BM) collection (group A, n ¼ 34); those who underwent second PBSC mobilization (group B, n ¼ 41); those in whom no further harvesting was carried out (group C, n ¼ 30). PBSC harvest yielded significantly more CD34 þ cells than BM collection. Autologous transplantation was performed in 30, 23 and 11 patients from groups A, B and C, respectively. Engraftment data and transplantation outcome did not differ significantly between groups A and C. By contrast, group B patients had a faster neutrophil recovery, required less platelet transfusions and experienced less transplant-related morbidity, as reflected by lower antibiotics needs and shorter hospital stays. In conclusion, remobilization of PBSC constitutes an effective approach to ensure a rapid hematopoietic engraftment and a safe transplantation procedure for poor mobilizers, whereas unprimed BM harvest does not provide any clinical benefit in this setting.
The optimal approach to obtain an adequate graft for transplantation in patients with poor peripheral blood stem cell (PBSC) mobilization remains unclear. We retrospectively assessed the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed PBSC mobilization in our institution. Such patients were distributed into three groups: those who proceeded to steady-state bone marrow (BM) collection (group A, n ¼ 34); those who underwent second PBSC mobilization (group B, n ¼ 41); those in whom no further harvesting was carried out (group C, n ¼ 30). PBSC harvest yielded significantly more CD34 þ cells than BM collection. Autologous transplantation was performed in 30, 23 and 11 patients from groups A, B and C, respectively. Engraftment data and transplantation outcome did not differ significantly between groups A and C. By contrast, group B patients had a faster neutrophil recovery, required less platelet transfusions and experienced less transplant-related morbidity, as reflected by lower antibiotics needs and shorter hospital stays. In conclusion, remobilization of PBSC constitutes an effective approach to ensure a rapid hematopoietic engraftment and a safe transplantation procedure for poor mobilizers, whereas unprimed BM harvest does not provide any clinical benefit in this setting. Bone Marrow Transplantation (2005) 36, 847-853. doi:10.1038/sj.bmt.1705147; published online 22 August 2005 Keywords: stem cell harvest; poor mobilization; autologous transplantation High-dose chemotherapy followed by autologous stem cell rescue has become the treatment of choice for several hematological malignancies and chemosensitive solid tumors. 1 Peripheral blood stem cells (PBSC) have virtually replaced bone marrow (BM) as the source of the progenitors in view of their faster engraftment kinetics. 2, 3 However, a minimum threshold level of 1-2 Â 10 6 CD34 þ cells/kg is considered essential to ensure a rapid hematopoietic reconstitution. 4, 5 Thus, patients undergoing myeloablative treatment supported by insufficient CD34 þ cells show delayed engraftment and increased transplant-related morbidity and mortality. In contrast, patients infused with 5 Â 10 6 CD34 þ cells/kg or more have earlier hematopoietic recovery, particularly of the megakaryocytic lineage, and a better outcome. 6, 7 Between 5 and 30% of patients do not mobilize sufficient PBSC to proceed to transplantation, depending on the target cell dose used. [7] [8] [9] Several factors have been associated with a poor mobilization including older age, 10 marrow disease, 6 prior myelosuppressive chemotherapy, 11 prior radiotherapy, 12 and low platelet or leukocyte counts at the time of apheresis. 13 Despite being a common clinical problem, the optimal strategy to obtain an adequate graft for transplantation in poor mobilizers remains unclear.
14 Remobilization of PBSC using hematopoietic cytokines alone [15] [16] [17] [18] [19] [20] or in combination with chemotherapy 5, 17 has proved to be a valid option in this situation. Alternatively, autologous BM progenitors can be harvested at steady state [21] [22] [23] [24] or following growth factor priming, 25 but this approach has been associated with variable results. 26 Finally, the infusion of grafts containing low CD34 þ cell contents may be considered in certain circumstances, though assuming the potential risks of a delayed engraftment. 4, 27 The aim of the present study was to retrospectively assess the impact of different strategies of second-line stem cell harvest on the transplantation outcome of patients who failed first line PBSC mobilization in our institution. Besides, an analysis of factors affecting the progenitor cell yield of the rescue harvest was performed.
Patients and methods

Patients' characteristics
From 1993 to 2003, 745 patients with malignancies consecutively underwent PBSC mobilization in our institution. Among them, 105 cases (14%) were considered mobilization failures, due to a collection yield of less than 2 Â 10 6 CD34 þ cells/kg, with such patients being the subject of the present study. In particular, mobilization failure was observed in 58 of 261 (22%) patients with chronic lymphoproliferative disorders (CLPD), 21 of 327 (6%) patients with breast cancer, 15 of 83 (18%) patients with acute leukemia, and 11 of 70 (16%) patients with miscellaneous diagnoses. The Institutional Review Board approved the protocols for stem cell collection and transplantation and written informed consent was obtained from every patient before the procedures. For the purpose of the study, patients who had failed PBSC mobilization were distributed into three groups depending on the strategy selected to obtain an adequate graft for autologous transplantation. Such strategy mainly depended on the time period in which the procedure was performed: thus, from 1993 to 1999, poor mobilizers generally proceeded to BM harvesting as the first line option (group A, n ¼ 34), whereas since 1999 most of them were scheduled for a second PBSC mobilization procedure (group B, n ¼ 41). A control group (group C, n ¼ 30) was formed with the remaining patients in whom no further attempts to collect more progenitors were performed due to: underlying disease in stable complete remission (n ¼ 15), early relapse (n ¼ 8), comorbidity (n ¼ 3), allogeneic stem cell transplantation (n ¼ 2), persistent pancytopenia (n ¼ 1), and renal failure caused by the previous PBSC mobilization regimen (n ¼ 1). The main clinicohematological characteristics of the patients included in each of the three groups are detailed in Table 1 . As can be seen, autologous stem cell transplantation was subsequently performed in 30, 23 and 11 patients from groups A, B and C, respectively.
Stem cell harvesting and cryopreservation
BM was harvested at steady state from both iliac crests using standard procedures (10-15 ml BM/kg body weight) at the time when the effects of the first mobilization regimen had vanished.
Second-line mobilization was performed with G-CSF 10 mg/kg daily (n ¼ 23), initiating the aphereses on day 4, or with G-CSF 5 mg/kg daily plus chemotherapy (usually cyclophosphamide 3 g/m 2 or iphosphamide 10 g/m 2 ) (n ¼ 18), collecting the PBSC when the leukocyte count increased above 5 Â 10 9 /l from the nadir (generally between days 11 and 15) or the CD34 þ counts on peripheral blood (PB) were above 5 cells/ml. 28 As a general rule, most patients were remobilized using a different strategy than that applied on the first mobilization attempt. Thus, patients failing to G-CSF alone were remobilized with chemotherapy plus G-CSF, whereas those failing to the combined regimen were subsequently mobilized using G-CSF alone. Stem cell aphereses were performed on 1-4 consecutive days using a continuous-flow cell separator (Baxter CS3000, Fenwal Laboratories, USA, and Cobe Spectra, Cobe Laboratories, USA). During each procedure two to three times the total patient's blood volume was processed for 3-4 h at flow rates of 50-60 ml/min through double-lumen apheresis catheters or peripheral venous access.
Prior to freezing, samples were taken from leukaphereses and BM products to estimate the number of mononucleated cells (MNC) and CD34 þ cells collected by flow cytometric analysis, evaluate their viability, and exclude possible microbiological contamination. The harvest products were then stored at À1961C in liquid nitrogen in cryopreservation bags (Hemofreezer) with a final dimethyl sulfoxid concentration of 10%.
Transplantation procedure
The main conditioning regimens were as follows: carmustine, etoposide, cytarabine and cyclophosphamide or melphalan (BEAC or BEAM) for patients diagnosed with lymphoma or chronic lymphocytic leukemia; busulfan with either cyclophosphamide or total body irradiation for patients with acute leukemia; busulfan and melphalan for those with multiple myeloma; and cyclophosphamide, thiotepa and carboplatin (STAMP-V) for breast cancer patients. Patients were nursed in single rooms in reverse isolation with high-efficiency particulate air filtered. G-CSF, at a dose of 5 mg/kg daily, was administered to all but acute myeloid leukemia patients from day 5 until neutrophil engrafment. Table 1 Clinical features of 105 patients who failed PBSC mobilization depending on the strategy of second-line stem cell harvest Packed red blood cells (RBC) and platelet transfusions were administered to keep the hemoglobin levels above 80 g/l and the platelet count above 10 Â 10 9 /l, respectively. One platelet transfusion refers to five pooled random donor units or one apheresis unit. Broad-spectrum antibiotics were given to patients who developed fever during neutropenia. Antifungal therapy was added when fever persisted after 96 h of intravenous antimicrobial therapy.
Time to hematopoietic reconstitution was defined as the number of days to achieve a neutrophil count higher than 0.5 Â 10 9 /l (first of 3 consecutive days) and an unsupported platelet count higher than 20 Â 10 9 /l. Multivariate regression analysis was used to determine which of the following factors influenced the progenitor cell yield of the rescue harvest: patients' age, gender, diagnosis, disease status, marrow disease, number of prior chemotherapy lines, mobilization regimen (growth factors alone or in combination with chemotherapy), interval between the first and second stem cell collection, and modality of stem cell harvest. When indicated, quantitative variables were transformed into binary variables using the median as a cutoff value. Besides, the correlation between the CD34 þ cell dose delivered to patients and the time to hematopoietic recovery was assessed by the Spearman's rank sum test. As a result of the skewed distribution of this variable, log transformation for the CD34 þ cell dose values was performed before the analysis.
Only probability values with Po0.05 were considered to be statistically significant. All computations were performed using SPSS software (12.0. version).
Results
Second-line stem cell collection
Group A patients (n ¼ 34) proceeded to BM harvesting at a median time of 5 weeks (range, 3-6) after the date of PBSC mobilization failure. The median total number of MNC ( Â 10 8 /kg) of the harvest was 2.2 (range, 1-5.3), with 21 patients achieving a yield of more than 2 Â 10 8 MNC/kg. Among the 16 patients with available data on CD34 þ cells, the median total CD34 þ cell yield ( Â 10 6 /kg) was 0.8 (range, 0.14-7.4), with only one patient achieving a harvest above the threshold of 2 Â 10 6 CD34 þ cells/kg.
Group B patients (n ¼ 41) underwent PBSC collection at a median time of 6 weeks (range, 3-189) after the first mobilization failure. The rest interval between mobilization attempts was longer in patients remobilized with G-CSF alone than in those using chemotherapy (9 vs 5 weeks; P ¼ 0.009). A median of two aphereses per patient (range, 1-4) were performed resulting in a median total CD34 þ cell yield ( Â 10 6 /kg) of 2 (range, 0.05-5.6), which was significantly higher than that obtained in the previous mobilization attempt (Po0.001). Of the 41 patients remobilized, 21 (51%) exceeded the threshold of 2 Â 10 6 CD34 þ cells/kg used to define a sufficient harvest. Taking together the collections from the first and second mobilization procedures, 31 patients (76%) achieved a cumulative progenitor yield above this minimum threshold. When analyzing the clinical profile of patients who reached the target CD34 þ cell dose of 2 Â 10 6 /kg, it could be seen that such patients were significantly younger than the remainder (median age: 43 vs 53 years; P ¼ 0.01), whereas no other clinical difference was observed between both groups.
On statistical analysis, the only factor significantly associated with the yield of CD34 þ cells was the modality of stem cell harvest. Thus, PBSC remobilization provided a higher CD34 þ cell yield than unprimed BM collection (P ¼ 0.01). Of note, second mobilization procedures with G-CSF alone or in combination with chemotherapy resulted in similar CD34 þ cell yields (data not shown). Table 2 outlines the main clinical characteristics of the series of 64 patients who underwent transplantation according to the strategy selected to obtain the progenitors for hematopoietic rescue. As can be seen, all groups were comparable with regard to most of their clinical features, with the only significant difference being the number of CD34 þ cells infused, which was higher in group B (Po0.0001).
Transplantation outcome
As far as engrafment is concerned, group B patients experienced a significantly faster hematopoietic reconstitution than patients from groups A and C, whereas the kinetics of the hematologic recovery was very similar in the latter two groups. Thus, the median time to neutrophil recovery was only 12 days in group B as compared to 17 and 19 days in groups A and C, respectively (P ¼ 0.003). Likewise, platelet recovery was observed earlier in group B, with a median time to achieve an unsupported platelet count of 20 Â 10 9 /l of 16 days in comparison with 28 and 27 days in groups A and C, respectively (P ¼ 0.02). As a consequence of the different pace in platelet engraftment, the transfusional needs varied significantly between the three groups, with the median number of platelet transfusions being 10, 4 and 7 for groups A, B and C, respectively (P ¼ 0.03). By contrast, packed RBC requirements did not differ significantly in all three categories. When the stability of engraftment was examined at 6 months after transplant, no significant differences in the median values of neutrophils, platelets and hemoglobin were observed between the three groups.
If consumption of intravenous antibiotics and hospital stay are considered as reasonable surrogate markers of patients' morbidity during transplantation, comparison of such parameters clearly favored group B patients over the others. Accordingly, the median time on parenteral antibiotics was 9 days in group B as opposed to 15 and 14 days in groups A and C, respectively (P ¼ 0.02). Moreover, the median times to hospital discharge were 24 days in group B compared to 30 and 32 days in groups A and C, respectively (P ¼ 0.006). No patients were readmitted into hospital after discharge due to late complications.
With regard to the relationship between CD34 þ cell dose and hematopoietic reconstitution, a significant inverse correlation was found between the number of CD34 þ cells infused and the times to achieve a neutrophil count higher than 0.5 Â 10 9 /l (R ¼ À0.48, Po0.0001) and an unsupported platelet count higher than 20 Â 10 9 /l (R ¼ À0.34, P ¼ 0.009), whereas the correlation with the time to platelet recovery to 50 Â 10 9 /l did not reach statistical significance (P ¼ 0.14). In the 34 patients receiving PBSC alone, the most discriminating cutoff value for a faster engraftment and a lower transplant-related morbidity probed to be 1.5 Â 10 6 CD34 þ cells/kg. Thus, patients receiving CD34 þ cells above this threshold value had a significant reduction in the time to neutrophil engraftment (12 vs 20 days; P ¼ 0.02) and hospital stay (24 vs 30 days; P ¼ 0.04).
Finally, five patients died between 13 and 102 days after transplant due to infections (n ¼ 4) and primary engraftment failure (n ¼ 1), the latter occurring in a patient with acute myeloid leukemia. Of note, three procedure-related deaths occurred in group A, all of them in patients receiving less than 1 Â 10 6 PB CD34 þ cells/kg. A detailed summary of the aforementioned results can be seen in Table 3 .
Discussion
ASCT constitutes the treatment of choice for several hematological malignancies and chemosensitive solid tumors. 1 However, an obvious prerequisite to apply this therapy is the availability of an adequate graft that assures a proper hematopoietic reconstitution after high-dose chemotherapy. In this sense, there is a general consensus that PB is the preferred anatomic source of the progenitors and that below a minimum threshold level of 1-2 Â 10 6 CD34 þ cells/kg, the risk of delayed hematopoietic engraftment and increased transplant-related morbidity and mortality is unacceptably high. 4, 5 According to these criteria, nearly a fifth of potential candidates to ASCT do not collect sufficient PBSC to proceed to transplantation following the first mobilization attempt. [7] [8] [9] 18 The optimal approach for stem cell collection in these patients is not as yet established. 14 In the present study, we review our experience on the management of poor mobilizers among a large series of 745 consecutive patients with malignancies who underwent Table 2 Patients' clinical characteristics at transplantation according to the strategy of second-line stem cell harvest No. of prior chemotherapy lines CD34 þ cells/kg, was 14%, a figure in keeping with that observed by other groups. 21, 25, 29 Of note, such complication was rare in patients with solid tumors, but occurred in up to 22% of patients with CLPD and 18% of those with acute leukemia. The primary aim of the study was to determine which of the two strategies employed to obtain rescue progenitors for poor mobilizers (ie, PBSC remobilization or unprimed BM harvesting) was associated with better transplantation results, both in terms of hematopoietic recovery and transplant-related morbidity. For comparison reasons, the transplantation outcome of 11 poor mobilizers who were infused grafts from a single PBSC harvest containing less than 2 Â 10 6 CD34 þ cells/kg during the study period served as control.
Prior to 1999, our general practice with poor mobilizers was to schedule an unprimed BM harvesting several weeks after the date of mobilization failure. Such procedure was disturbing for the patients and the yield of stem cells was poor, only occasionally reaching the target cell dose of 2 Â 10 6 CD34 þ cells/kg. In all, 30 of these patients eventually underwent autologous transplantation, with their clinical outcome being superimposable to that observed in the control group. In this sense, the infusion of additional BM progenitors was not associated with any significant benefit regarding the rapidity of the engraftment, the transfusional requirements or the duration of hospital stay. Previous experiences on the use of unprimed BM in this setting are limited, [21] [22] [23] [24] but their findings are in line with the present ones. Thus, Watts et al 21 reported a delayed engraftment and a high transplant-related morbidity and mortality in 12 patients in whom rescue BM progenitors were collected after PBSC mobilization failure (defined as o1 Â 10 6 CD34 þ cells/kg). Similarly, BM harvest failed to provide sufficient amounts of CD34 þ progenitors (target dose 42.5 Â 10 6 /kg) in a series of seven lymphoma patients reported by Sugrue et al 23 five of which showed slow platelet recovery and a high incidence of disease progression after transplantation. In contrast with the aforementioned reports, efective multilineage hematopoietic recovery and a low transplant-related mortality was observed using G-CSF-primed BM in a large series of 86 poor mobilizers with different hematological malignancies. 25 Interestingly, in this study the median number of CD34 þ cells reinfused was only 0.7 Â 10 Since 1999, an alternative policy was instituted in our centre to collect additional progenitors for poor mobilizers, which consisted on performing a second PBSC mobilization procedure using a different regimen than that applied on the previous mobilization attempt. Such strategy was associated with substantial mobilization of CD34 þ cells that generally exceeded that obtained in the first attempt. In fact, about half the patients achieved the target CD34 þ cell dose in the second procedure, and over three-quarters if cells from both harvest procedures were pooled together.
Besides, the increase in CD34 þ cell collection was translated into a better transplantation outcome, as supported by the faster hematopoietic engraftment and the decreased transplantation morbidity registered in these patients. Thus, if compared with data from the control group, median times to neutrophil and platelet recovery were 7 and 11 days shorter, respectively; needs of antibiotics and platelet transfusions were significantly reduced; and importantly, median hospital stay was over a week shorter. As noted in previous reports, the total CD34 þ cell dose of the graft correlated with the rapidity of engraftment. [30] [31] [32] Similar strategies for PBSC rescue mobilization have been investigated by other groups, 5, [15] [16] [17] [18] [19] [20] but comparison of the results is difficult due to the heterogeneity of the published studies. In general, G-CSF, at doses of 10 mg/kg/day 15, 17 or higher, 17, 18 is the agent most commonly employed for this purpose. In this respect, the largest series published to date 19 included 138 patients who were remobilized using G-CSF alone, at a dose of 10 mg/kg/ day, after a 7-day resting period: such regimen provided a harvest of more than 2.5 Â 10 6 CD34 þ cells/kg in 65% of patients and, remarkably, the median times to neutrophil and platelet recovery after transplantation were 13 and 14 days, respectively. On the other hand, the use of G-CSF in combination with chemotherapy has largely been superior to G-CSF alone for first line 33, 34 as well as second-line mobilization attempts. 35, 36 However, repetition of a chemotherapy plus cytokine regimen in patients who have already failed to this strategy may be associated with an increased toxicity, 5, 17 and therefore may not be the preferred approach for such patients. In this sense, the data presented here are in keeping with previous reports 15, 17, 19 showing that G-CSF alone can be as effective as chemotherapy plus G-CSF for second attempts of PBSC mobilization in this situation.
Based on the present results and on previous studies, it can be concluded that remobilization of PBSC constitutes an effective approach to ensure a rapid hematopoietic engraftment and a safe transplantation procedure for poor mobilizers, whereas unprimed BM harvest does not provide any clinical benefit in this setting. Nevertheless, since with the current strategies not all patients succeed to obtain a sufficient graft for transplantation, investigation of new options is warranted. In this sense, a recent report indicating that the addition of recombinant human growth hormone to G-CSF permitted the achievement of 42 Â 10 6 CD34 þ cells/kg in all 16 patients who had failed a first mobilization attempt, 16 seems promising. 
